Get started
Longeveron Inc.Longeveron Inc.Longeveron Inc.

Longeveron Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

LGVN trade ideas

LGVN - Biotech - Pre data realese pump expected - fast play!Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty. Float 12.465M Phase 2a - Data Releas on 21/10/2024 Overall Market Sentiment: It’s always crucial to consider overall market sentiment when making trading decisions. Resistance Points: $2.80 $3.49 Surpassing these levels could signal a positive trend. Consider taking profits at these stages to realize gains. Trading Strategy: I expect a quick pre-pump before the news. Afterwards, it could crash hard, so stay ready and be careful. Take Profit (TP): Set a target at $4.00 (pre catalyst run up) Stop Loss (SL): Set at under $1.9 to mitigate potential losses. Chart Analysis: Please refer to the attached chart for detailed analysis of price trends and movements. Trading Advisory: Exercise caution and consider market conditions and your own risk tolerance when trading. It's advisable to conduct comprehensive research or consult with a financial advisor before engaging in trading activities. Disclaimer: This content is for informational purposes only and should not be considered financial advice.
NASDAQ:LGVNLong
by meitshels_smell_trades
LGVN - another short squeeze leg up ahead - 49% short flaotLongeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty. This is a high risk idea - keep this in mind! Short float: 49% Shares float 4.4M Borrow Fee: 625% Passive stake of 676'229 shares on Friday , July 26 Breakout Zone: $4.0 Action: If the stock breaks above this area with strong volume, it might signal a continuation of the upward trend. Overall Market Sentiment: Currently, the market seems to be in a correction phase. It’s crucial to consider this sentiment when making trading decisions. Resistance Points: $4.00 $5.40 $6.40 Surpassing these levels could signal a positive trend. Consider taking profits at these stages to realize gains. Trading Strategy: Take Profit (TP): Set a target at $10.00 or even $15.00 is possible. Stop Loss (SL): Set at under $2.50 to mitigate potential losses. Chart Analysis: Please refer to the attached chart for detailed analysis of price trends and movements. Trading Advisory: Exercise caution and consider market conditions and your own risk tolerance when trading. It's advisable to conduct comprehensive research or consult with a financial advisor before engaging in trading activities. Disclaimer: This content is for informational purposes only and should not be considered financial advice.
NASDAQ:LGVNLong
by meitshels_smell_trades
LGVN Fish Hook PatternNASDAQ:LGVN The clinical stage biotechnology company developing cellular therapies for life-threatening conditions, Longeveron Inc. (NASDAQ: LGVN) has been regaining some of the momentum it lost following its 128% surge. Considering that its Alzheimer's treatment showed impressive results in its phase 1 trials, many investors believe LGVN stock could be a profitable long-term play. LGVN stock price is currently $11.38 as the stock trades near its resistance at $11.56. LGVN stock shows a stronger resistance at $12.89 with a main support at $8.87 and a weaker support at $10.62. After surging 128% at the end of March with news of Lomecel-B’s positive results, accumulation has been falling. The MACD is currently bearish and the RSI is resting at 53. Overall this price action appears to be forming a fish hook chart pattern on the daily chart. The fish hook chart pattern is characterized by rapid selling over a number of days – which we can see with the 20% drop starting on the 5th. Gradually, selling slows as panic selling stops and a brief period of consolidation follows. This is when the RSI drops near 30 which happened with LGVN stock around the 11th. Since then the RSI has increased rapidly, forming the last leg of the chart pattern – resulting in the roughly 40% increase over the last few days as volume poured in. With the pattern almost complete, it may be risky to enter now. But LGVN stock could see a further increase depending on volume. With a low float of 4.46 million, LGVN stock shows significant volatility and typically runs on positive news. But like many biotech and pharma stocks, LGVN stock is a long-term investment for most investors holding out for FDA approval and commercialization. In this way, LGVN stock moves on binary events with lulls in between. Given that Lomecel-B showed encouraging results in its phase 1 trials, LGVN’s treatment could have significant upside potential if it is able to continue achieving positive results in these larger clinical trials. Meanwhile, investors will be watching for LGVN’s next quarterly report after the positive results of its last report. If the company makes consistent progress this year in securing grants it will help offset the costs of its clinical trials putting the company in a better financial position. But as is, LGVN is confident that it has the funding to sustain its operations well into 2024 which lowers the risk of dilution. In light of this, many investors are bullish on LGVN stock’s long-term potential.
NASDAQ:LGVN
by Penny_Stocks_Today
1
$LGVN – SI 65%Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
NASDAQ:LGVNLong
by BADQOMOCAWGOWLD
$LGVN entry PT 25 Target PTs 43-49 and higherLongeveron stock is up by a multiple of 11 after the FDA gave a Rare Pediatric Disease designation for a heart medication last week. Longeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
NASDAQ:LGVNLong
by BADQOMOCAWGOWLD
1
$LGVNLongeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
NASDAQ:LGVNLong
by BADQOMOCAWGOWLD
3